GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CollPlant Biotechnologies Ltd (XTAE:CLGN) » Definitions » Forward PE Ratio

CollPlant Biotechnologies (XTAE:CLGN) Forward PE Ratio : 16.41 (As of May. 27, 2024)


View and export this data going back to 2007. Start your Free Trial

What is CollPlant Biotechnologies Forward PE Ratio?

CollPlant Biotechnologies's Forward PE Ratio for today is 16.41.

CollPlant Biotechnologies's PE Ratio without NRI for today is 144.04.

CollPlant Biotechnologies's PE Ratio for today is 0.00.


CollPlant Biotechnologies Forward PE Ratio Historical Data

The historical data trend for CollPlant Biotechnologies's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CollPlant Biotechnologies Forward PE Ratio Chart

CollPlant Biotechnologies Annual Data
Trend
Forward PE Ratio

CollPlant Biotechnologies Quarterly Data
Forward PE Ratio

Competitive Comparison of CollPlant Biotechnologies's Forward PE Ratio

For the Biotechnology subindustry, CollPlant Biotechnologies's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CollPlant Biotechnologies's Forward PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CollPlant Biotechnologies's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where CollPlant Biotechnologies's Forward PE Ratio falls into.



CollPlant Biotechnologies Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


CollPlant Biotechnologies  (XTAE:CLGN) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


CollPlant Biotechnologies Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of CollPlant Biotechnologies's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


CollPlant Biotechnologies (XTAE:CLGN) Business Description

Traded in Other Exchanges
Address
4 Oppenheimer Street, P.O. Box 4132, Weizmann Science Park, Rehovot, ISR, 7670104
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The company's revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing.